---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-005619"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2025-01-23T23:59:59+00:00"
generated_at: "2026-05-27T14:35:28.731765+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Quoin reports reversal of QRX003 benefits 4 weeks post-discontinuation in Netherton syndrome study

## Summary
- M-IASI score returned from 3 (12 weeks) to 18 at 4 weeks post-discontinuation, equaling baseline of 18.
- WINRS (itch) worsened from 2 at 12 weeks to 8 post-discontinuation, exceeding baseline of 7.
- IGA regressed from 'Almost Clear' at 12 weeks back to 'Moderate', same as baseline.
- Data from first twice-daily dosed subject shows complete reversal of all clinical improvements after stopping QRX003.

## SEC filing metadata
- accession: 0001104659-25-005619
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2025-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465925005619/0001104659-25-005619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465925005619/tm254263d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-005619
- JSON: https://secwatch.observer/filing/0001104659-25-005619.json
- Plain text: https://secwatch.observer/filing/0001104659-25-005619.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.